Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis.

ABSTRACT: Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit-risk profile. https://bit.ly/3SbisW3.

SUBMITTER: Chalmers JD 

PROVIDER: S-EPMC10152260 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature